SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-005220
Filing Date
2023-03-02
Accepted
2023-03-02 16:11:17
Documents
15
Period of Report
2023-03-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20230222_8k.htm   iXBRL 8-K 25263
2 EXHIBIT 99.1 ex_482630.htm EX-99.1 183323
7 p01.jpg GRAPHIC 3075
  Complete submission text file 0001437749-23-005220.txt   362869

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20230302.xsd EX-101.SCH 3600
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20230302_def.xml EX-101.DEF 11531
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20230302_lab.xml EX-101.LAB 15413
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20230302_pre.xml EX-101.PRE 11687
9 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20230222_8k_htm.xml XML 2573
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 23699029
SIC: 2834 Pharmaceutical Preparations